Pharmacology of Tezosentan, New Endothelin Receptor Antagonist Designed for Parenteral Use

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Yung-Chi Cheng, William H. Prusoff · Biochemical Pharmacology · 1973 · 12.9K citations

Life Sciences, Biochemistry, Chemical Kinetics +14

SOME QUANTITATIVE USES OF DRUG ANTAGONISTS

O. ARUNLAKSHANA, H. O. Schild · British Journal of Pharmacology and Chemotherapy · 1959 · 4K citations · Full text

Medicine, Pharmacology, General Pharmacology +16

Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.

Martine Clozel, Volker Breu, Gillian A. Gray et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 668 citations

Medicine, Medicinal Chemistry, Pharmacology +15

Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure

Wolfgang Kiowski, J Kim, Erwin Oechslin et al. · The Lancet · 1995 · 573 citations

Life Sciences, Cardiology, Physiology +11

Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.

Bojung Seo, Barry S. Oemar, R Siebenmann et al. · Circulation · 1994 · 515 citations

Life Sciences, Pharmacology, Physiology +12